English | 2cureX

Regulatory Show all

May 28 | 2020

Communique from the Annual General Meeting in 2cureX AB (publ)

May 28 | 2020

2cureX publishes interim report for the first quarter of 2020

May 7 | 2020

2cureX publishes the annual report for the fiscal year 2019

April 29 | 2020

2cureX German subsidiary receives a grant contribution to support the activities towards automation of the IndiTreat® test

April 28 | 2020

Notice of annual general meeting of 2cureX AB (publ)

April 6 | 2020

2cureX, Germany receives an additional grant for adapting IndiTreat® to guide immunotherapy of ovarian cancer patients

April 2 | 2020

2cureX establish clinical partnership with Skåne University Hospital, Sweden

March 23 | 2020

2cureX provides update regarding the COVID-19 impact on ongoing clinical programs

March 12 | 2020

COVID-19 precautions: Remote setup secure continued sample screening supporting cancer patients

March 6 | 2020

2cureX is accelerating the commercialization of IndiTreat® by signing two distributor agreements to prepare for launch in second half of 2020

February 28 | 2020

2cureX publishes year-end report for 2019

January 30 | 2020

Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test

January 6 | 2020

2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia

January 2 | 2020

Steady progress for 2cureX in 2019

December 13 | 2019

Hospitals and cancer care givers can now offer the IndiTreat test to their cancer patients.